What is Zolgensma's legacy in the drug pricing debate?
Zolgensma set the gene-therapy price reference point — Elevidys later launched at $3.2 million — while its data manipulation episode raised questions about self-reporting reliability, demonstrating both the promise of one-time curative therapies and the unresolved problems of paying for and validating them.
Zolgensma set the reference point for gene therapy pricing. As Health Affairs warned, once one drug sets the price level in a category, future drugs tend to be priced in the same range or higher; Sarepta's Elevidys later launched at $3.2 million. The data manipulation episode also raised questions about whether regulators can rely on sponsors' self-reporting, particularly under pressure to approve therapies for fatal diseases quickly. On the other hand, the therapy's clinical benefit has been substantial, and ICER ultimately judged its price within a defensible range under generous assumptions. The Zolgensma case therefore demonstrates both the promise of gene therapy and the unresolved problems of how society pays for one-time treatments, and how it ensures the data behind them are sound.